Eli Lilly and Company and BioNTech AG announced that they have signed a research
collaboration agreement for the discovery of novel cancer
immuno-therapies.Under this partnership, both companies will work on identifying and
validating novel tumor targets and their corresponding T cell
receptors (TCRs) in one or more types of cancer.
Eli Lilly will make a $30 million equity investment
in BioNTech's subsidiary, Cell & Gene Therapies GmbH, which
specializes in the research and development of TCR and chimeric
antigen receptor immunotherapeutics. Additionally, Eli Lilly will
pay development, regulatory and commercial milestones of over $300
million for each potential therapy developed under this
collaboration, apart from a signing fee of $30 million. Upon the
successful commercialization of the drugs, BioNTech will be
entitled to receive tiered royalty payments in up to double digits.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment